--- title: "Equillium (EQ) news: reverse split and offering" url: "https://aibio.space/companies/equillium/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EQ reverse split and offering news: Equillium gets 180 more days from Nasdaq to meet minimum bid price requirement. Equillium, Inc." --- EQ Equillium, Inc. NASDAQ · United States # Equillium (EQ) news EQ reverse split and offering news Financings · 2026-10-26 ## [First EQ504 dosing unlocks a $20 million private placement tranche for Equillium](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/) Equillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029. ## Latest Equillium news 1. 2026-08-13 Company Updates [Equillium expects EQ504 Phase 1 start in Q4 2026 and cash into 2029](https://aibio.space/news/equillium-expects-eq504-phase-1-start-q4-2026-cash-2029/) Equillium reported a second-quarter net loss of $4.7 million and cash and cash equivalents of $57.2 million at June 30, 2026, which it says can fund planned operations into 2029. 2. 2026-05-13 Company Updates [Equillium names Snehal Naik chief development officer and reports Q1 2026 results](https://aibio.space/news/equillium-names-snehal-naik-chief-development-officer-reports-q1-2026/) Equillium said cash and cash equivalents were $61.3 million at March 31, 2026, following a $35 million private placement with RA Capital Management completed in March 2026. 3. 2025-09-19 Financings [Equillium expands at-the-market stock program to up to $75,000,000](https://aibio.space/news/equillium-expands-market-stock-program-up-75-000-000/) Equillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus. 4. 2025-09-04 Listings [Equillium regains compliance with Nasdaq's $1.00 minimum bid price rule](https://aibio.space/news/equillium-regains-compliance-nasdaqs-1-00-minimum-bid-price-rule/) Nasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days. 5. 2025-06-13 Listings [Equillium gets 180 more days from Nasdaq to meet minimum bid price requirement](https://aibio.space/news/equillium-gets-180-more-days-nasdaq-meet-minimum-bid-price-requirement/) Nasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ". ## Equillium at a glance - **Ticker**: EQ - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $57.2 million ### Related companies - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) NASDAQ: RLAY - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [AquaBounty Technologies](https://aibio.space/companies/aquabounty-technologies/) NASDAQ: AQB ### Also on NASDAQ - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB - [Enlivex](https://aibio.space/companies/enlivex/) ENLV - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) ACAD - [ORTHOPEDIATRICS CORP](https://aibio.space/companies/orthopediatrics/) KIDS - [Intercure](https://aibio.space/companies/intercure/) INCR - [Foghorn Therapeutics](https://aibio.space/companies/foghorn-therapeutics/) FHTX ## Equillium annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$41.1 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | | Net income (loss) | [-$22.4 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | [-$8.1 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | | Cash from operations | [-$22.7 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | [-$19.0 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | | Cash and equivalents | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349235/) | [$18.1 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | | Short-term investments | | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $57.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Equillium Did Equillium do a reverse stock split? Our latest story on this, dated Jun 13, 2025: "Equillium gets 180 more days from Nasdaq to meet minimum bid price requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/equillium-gets-180-more-days-nasdaq-meet-minimum-bid-price-requirement/). Has Equillium raised money recently? Our latest story on this, dated Oct 26, 2026: "First EQ504 dosing unlocks a $20 million private placement tranche for Equillium". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/). What is the ticker symbol of Equillium? Equillium, Inc. trades under the ticker EQ on NASDAQ. Where is Equillium listed? Equillium, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0FY; LSE:0A4D. What is the SEC CIK of Equillium? The SEC Central Index Key (CIK) for Equillium, Inc. is 1746466. Its filings are on SEC EDGAR. How many shares does Equillium have outstanding? 63,408,082 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Equillium listed under? Our directory records Equillium, Inc. under United States. What does Equillium do? Our directory classifies Equillium, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Equillium? The ISIN recorded for Equillium, Inc. is US29446K1060. Does aibio.space cover Equillium? aibio.space lists Equillium, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Equillium incorporated? SEC records list its state or country of incorporation as DE. Is Equillium profitable? Equillium, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $22.7 million of cash in operations, per its annual report to the SEC. How much cash does Equillium have? $57.2 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Equillium (EQ) stock news? Our latest story on Equillium, dated Oct 26, 2026: "First EQ504 dosing unlocks a $20 million private placement tranche for Equillium". Equillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029. [Source](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/). How long will Equillium's cash last? From our story of Oct 26, 2026: The company says that with this closing its cash should fund planned operations into 2029. [Source](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/). ## Investor discussion: Equillium Members talk about Equillium (EQ). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Equillium, newest first. Each line links the filing it comes from. 1. 2026-10-26 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526432158/d67574dex991.htm) 2. 2026-05-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526248246/d148127d8k.htm) 3. 2026-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526156092/eq-20260414.htm) 4. 2026-03-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526132029/eq-20260330.htm) 5. 2026-03-25 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/eq-20251231.htm) 6. 2026-03-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312526105083/d125584d8k.htm) 7. 2025-10-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312525231860/d930780d8k.htm) 8. 2025-09-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312525209063/d47819d424b5.htm) 9. 2025-09-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000095017025113023/eq-20250829.htm) 10. 2025-08-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312525177510/d448302d8k.htm) 11. 2025-06-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000095017025086155/eq-20250612.htm) 12. 2025-05-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312525125153/d100783d8k.htm) 13. 2025-04-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000095017025052669/eq-def14a-2025.htm) 14. 2025-03-28 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000095017025046333/eq-pre14a-2025.htm) 15. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm) 16. 2024-12-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312524278465/d903111d8k.htm) 17. 2024-10-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1746466/000119312524247760/d908344d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EQ on TradingView](https://www.tradingview.com/symbols/NASDAQ-EQ/). ## SEC filings and registration - **SEC name**: Equillium, Inc. - **CIK**: 1746466 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: EQ (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037 - **Phone**: (858) 412-5302 - **Shares outstanding**: 63,408,082 as of 2026-08-07 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1746466/000119312526414364/d174431d8k.htm) filed 2026-10-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349235/eq-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1746466/000119312526248246/d148127d8k.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000119312526221625/eq-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-20260513.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1746466/000119312526156092/eq-20260414.htm) filed 2026-04-15 - [S-3](https://www.sec.gov/Archives/edgar/data/1746466/000119312526145746/d116924ds3.htm) filed 2026-04-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001746466), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Equillium, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EQ, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Equillium, Inc. - **Ticker**: EQ - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US29446K1060 - **Other listed symbols**: GETTEX:0FY; LSE:0A4D - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-EQ/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/equillium/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Equillium (EQ) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/equillium/